Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Breast Cancer

Free Subscription 06.05.2024 2 AJR Am J Roentgenol 2 Am J Clin Pathol 1 Ann Oncol 2 Ann Surg Oncol 5 Anticancer Res 2 BMC Cancer 3 Breast Cancer 1 Breast Cancer (Dove Med Press) 1 Breast Cancer Res 11 Breast Cancer Res Treat 1 Cancer Chemother Pharmacol 4 Cancer Epidemiol Biomarkers Prev 2 Cancer Lett 1 Cell 3 Clin Breast Cancer 1 Eur J Surg Oncol 1 Eur Radiol 2 Int J Cancer 1 Int J Radiat Oncol Biol Phys 1 J Biol Chem 1 J Clin Oncol 1 J Surg Oncol 7 JAMA 1 Lancet 1 Lancet Oncol 1 Nat Rev Cancer 1 NPJ Breast Cancer 3 Oncogene 1 PLoS Comput Biol 2 PLoS One 2 Radiology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. YEH ED
   Editorial Comment: Breast Cryoablation-A Promising Technology to Nonsurgically Treat Small Low-Risk Breast Cancer.
   AJR Am J Roentgenol. 2024 May 1. doi: 10.2214/AJR.24.31346.
   PubMed        
   
   
2. HUANG ML, Lane DL, Santiago L
   MRI-Guided Breast Cryoablation With the Patient in Prone Position.
   AJR Am J Roentgenol. 2024 Feb 14. doi: 10.2214/AJR.23.30754.
   PubMed        
   
   

   
   Am J Clin Pathol

3. HARTSOUGH E, DeSimone MS, Lorenzo ME, Dias-Santagata D, et al
   Utilizing PTEN immunohistochemistry as a screening test for Cowden syndrome.
   Am J Clin Pathol. 2024;161:490-500.
   PubMed         Abstract available
   
   
4. KOWALEWSKI A, Klijanienko J
   Cytologic analysis of metaplastic breast carcinoma: Review of 66 cases diagnosed at the Institut Curie.
   Am J Clin Pathol. 2024;161:430-435.
   PubMed         Abstract available
   
   

   
   Ann Oncol

5. PUSZTAI L, Denkert C, O'Shaughnessy J, Cortes J, et al
   Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.
   Ann Oncol. 2024;35:429-436.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

6. JUNG JJ, Cheun JH, Kang E, Shin I, et al
   Survival After Contralateral Axillary Metastasis in Breast Cancer.
   Ann Surg Oncol. 2024 May 2. doi: 10.1245/s10434-024-15370.
   PubMed         Abstract available
   
   
7. KAUFMAN C, Sarantou T, Donovan C, Kamali Polat A, et al
   ASO Author Reflections: Increasing Time of Diagnosis to Breast Cancer Surgery.
   Ann Surg Oncol. 2024 Apr 29. doi: 10.1245/s10434-024-15295.
   PubMed        
   
   

   
   Anticancer Res

8. VANNI G, Materazzo M, Lorenzo ND, Tacconi F, et al
   Contrast-enhanced Ultrasound Using Intradermal Microbubble Sulfur Hexafluoride in Non-invasive Axillary Staging in Breast Cancer: Are we Missing a Chance?
   Anticancer Res. 2024;44:2021-2030.
   PubMed         Abstract available
   
   
9. GOROBETS O, Keam B, Vinh-Hung V, Nguyen NP, et al
   Twenty-five Years Overall Survival Prognostic Value of the Lymph Node Ratio in De Novo Metastatic Breast Cancer.
   Anticancer Res. 2024;44:1995-2002.
   PubMed         Abstract available
   
   
10. CIPOLLA C, Lupo S, Grassi N, Battaglia MC, et al
    The Impact of Neoadjuvant Chemotherapy on Axillary Surgical Management of Patients With Breast Cancer and Positive Axillary Lymph Nodes.
    Anticancer Res. 2024;44:2047-2053.
    PubMed         Abstract available
    
    
11. PERRONE E, Taralli S, Pagliara D, Larocca LM, et al
    Breast Relapse of Pediatric B-Cell Acute Lymphoblastic Leukemia After CAR-T Therapy Detected by (18)F-FDG PET/CT.
    Anticancer Res. 2024;44:2243-2245.
    PubMed         Abstract available
    
    
12. PSEFTOGAS A, Xanthopoulos K, Siasiaridis A, Poutahidis T, et al
    Inactivation of the Tumor Suppressor CYLD Sensitizes Mice to Breast Cancer Development.
    Anticancer Res. 2024;44:1885-1894.
    PubMed         Abstract available
    
    

    
    BMC Cancer

13. WANG J, Tian C, Zheng BJ, Zhang J, et al
    The use of longitudinal CT-based radiomics and clinicopathological features predicts the pathological complete response of metastasized axillary lymph nodes in breast cancer.
    BMC Cancer. 2024;24:549.
    PubMed         Abstract available
    
    
14. HAN JY, Che N, Mo J, Zhang DF, et al
    Desmoglein 2 and desmocollin 2 depletions promote malignancy through distinct mechanisms in triple-negative and luminal breast cancer.
    BMC Cancer. 2024;24:532.
    PubMed         Abstract available
    
    

    
    Breast Cancer

15. LEE SJ, Cha CD, Hong H, Choi YY, et al
    Adverse effects of tamoxifen treatment on bone mineral density in premenopausal patients with breast cancer: a systematic review and meta-analysis.
    Breast Cancer. 2024 Apr 27. doi: 10.1007/s12282-024-01586.
    PubMed         Abstract available
    
    
16. KAWAMOTO H, Tsugawa K, Furuya Y, Sakamaki K, et al
    Percutaneous ultrasound-guided cryoablation for early-stage primary breast cancer: a follow-up study in Japan.
    Breast Cancer. 2024 Apr 27. doi: 10.1007/s12282-024-01584.
    PubMed         Abstract available
    
    
17. SHIMOMURA A, Sagara Y, Koto R, Fujiwara M, et al
    Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan.
    Breast Cancer. 2024 Apr 29. doi: 10.1007/s12282-024-01572.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

18. ZHOU YH, Huang JY
    Expression and Significance of LINC02418 in Breast Cancer.
    Breast Cancer (Dove Med Press). 2024;16:233-243.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

19. SMITH RE, Sprague BL, Henderson LM, Kerlikowske K, et al
    Breast density knowledge and willingness to delay treatment for pre-operative breast cancer imaging among women with a personal history of breast cancer.
    Breast Cancer Res. 2024;26:73.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

20. TENG YT, Wang YA, Dong YH, Liu JJ, et al
    Correction: Five-year survival prognosis of young, middle-aged, and elderly adult female invasive breast cancer patients by clinical and lifestyle characteristics.
    Breast Cancer Res Treat. 2024 May 2. doi: 10.1007/s10549-024-07335.
    PubMed        
    
    
21. PIZZAMIGLIO S, Ciniselli CM, de Azambuja E, Agbor-Tarh D, et al
    Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTO.
    Breast Cancer Res Treat. 2024 Apr 30. doi: 10.1007/s10549-024-07299.
    PubMed         Abstract available
    
    
22. MORAD A, Johnson K, Bate S, Birkby I, et al
    Ten-year trend analysis of breast cancer, oncoplastic, and reconstructive breast surgery in a single institution (2010-2019), what has not changed?
    Breast Cancer Res Treat. 2024 Apr 30. doi: 10.1007/s10549-024-07294.
    PubMed         Abstract available
    
    
23. SCHAFFAR R, Benhamou S, Chappuis PO, Rapiti E, et al
    Risk of first recurrence after treatment in a population-based cohort of young women with breast cancer.
    Breast Cancer Res Treat. 2024 Apr 30. doi: 10.1007/s10549-024-07338.
    PubMed         Abstract available
    
    
24. HIJAZI A, Mohanna M, Sabbagh S, Herran M, et al
    Clinico-pathologic factors and survival of patients with breast cancer diagnosed with de novo brain metastasis: a national cancer database analysis.
    Breast Cancer Res Treat. 2024 Apr 29. doi: 10.1007/s10549-024-07321.
    PubMed         Abstract available
    
    
25. ROBERTS A, Hallet J, Nguyen L, Coburn N, et al
    Neoadjuvant chemotherapy for triple-negative and Her2 +ve breast cancer: striving for the standard of care.
    Breast Cancer Res Treat. 2024 Apr 27. doi: 10.1007/s10549-024-07282.
    PubMed         Abstract available
    
    
26. BRABENDER D, Ballard A, Kim S, Hovanessian-Larsen L, et al
    Use of ultrasound and MRI to stage the axilla for breast cancer before and after neoadjuvant chemotherapy prior to targeted sentinel lymphadenectomy.
    Breast Cancer Res Treat. 2024 May 3. doi: 10.1007/s10549-024-07332.
    PubMed         Abstract available
    
    
27. LUSTBERG M, Fan-Havard P, Wong FL, Hill K, et al
    Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial.
    Breast Cancer Res Treat. 2024;205:61-73.
    PubMed         Abstract available
    
    
28. JORGENSEN SF, Sagstad S, Louro J, Roman M, et al
    Comparisons of assessment pathways after abnormal mammography screening in Denmark, Norway, and Spain.
    Breast Cancer Res Treat. 2024;205:135-145.
    PubMed         Abstract available
    
    
29. WUYTS K, Durston V, Morstyn L, Mills S, et al
    Information needs in breast reconstruction after mastectomy: a qualitative analysis of free-text responses from 2077 women.
    Breast Cancer Res Treat. 2024;205:147-157.
    PubMed         Abstract available
    
    
30. BISSELL MB, Keshavarsi S, Fleming R, Au F, et al
    MRI-visualized T2 hyperintense breast lesions: identifying clinical and imaging factors linked to malignant biopsy outcomes.
    Breast Cancer Res Treat. 2024;205:159-168.
    PubMed         Abstract available
    
    

    
    Cancer Chemother Pharmacol

31. GHORBANI M, Namazi S, Dehghani M, Razi F, et al
    Gene polymorphisms of TACR1 serve as the potential pharmacogenetic predictors of response to the neurokinin-1 receptor antagonist-based antiemetic regimens: a candidate-gene association study in breast cancer patients.
    Cancer Chemother Pharmacol. 2024 Apr 27. doi: 10.1007/s00280-024-04661.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

32. PARK JE, Smith MA, Van Alsten SC, Walens A, et al
    Diffsig: Associating Risk Factors with Mutational Signatures.
    Cancer Epidemiol Biomarkers Prev. 2024;33:721-730.
    PubMed         Abstract available
    
    
33. VAN ALSTEN SC, Dunn MR, Hamilton AM, Ivory JM, et al
    Disparities in OncotypeDx Testing and Subsequent Chemotherapy Receipt by Geography and Socioeconomic Status.
    Cancer Epidemiol Biomarkers Prev. 2024;33:654-661.
    PubMed         Abstract available
    
    
34. JATOI I
    Breast Cancer Screening: Can We Justify Deescalation?
    Cancer Epidemiol Biomarkers Prev. 2024;33:638-640.
    PubMed         Abstract available
    
    
35. FREEMAN JQ, Huo D
    Addressing Social Determinants in the Era of Precision Medicine in Breast Cancer: Is It Sufficient to Reduce Disparities?
    Cancer Epidemiol Biomarkers Prev. 2024;33:635-637.
    PubMed         Abstract available
    
    

    
    Cancer Lett

36. ZHANG Y, Tan Y, Yuan J, Tang H, et al
    circLIFR-007 reduces liver metastasis via promoting hnRNPA1 nuclear export and YAP phosphorylation in breast cancer.
    Cancer Lett. 2024;592:216907.
    PubMed         Abstract available
    
    
37. SONG Y, Ren S, Chen X, Li X, et al
    Inhibition of MFN1 restores tamoxifen-induced apoptosis in resistant cells by disrupting aberrant mitochondrial fusion dynamics.
    Cancer Lett. 2024;590:216847.
    PubMed         Abstract available
    
    

    
    Cell

38. KONG LR, Gupta K, Wu AJ, Perera D, et al
    A glycolytic metabolite bypasses "two-hit" tumor suppression by BRCA2.
    Cell. 2024;187:2269-2287.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

39. BAUMGARTEN MW, Goemann IM, Scheffel RS, Maia AL, et al
    Survival Outcomes in Thyroid Cancer Patients with Co-Occurring Breast Cancer: Evidence of Mortality Risk Attenuation.
    Clin Breast Cancer. 2024 Apr 6:S1526-8209(24)00102.
    PubMed         Abstract available
    
    
40. GRUBSTEIN A, Dahan M, Jomar W, Friehmann T, et al
    Screening Mammography for Males With Elevated Breast Cancer Risk, Mutation Carriers, and Gynecomastia.
    Clin Breast Cancer. 2024 Apr 4:S1526-8209(24)00100.
    PubMed         Abstract available
    
    
41. CHEN X, Wei X, Yao P, Liu Y, et al
    The Efficiency and Toxicity Of Anlotinib in Combination With Docetaxel Followed by Epirubicin and Cyclophosphamide Regimen as Neoadjuvant Treatment in IIB to IIIA Triple Negative Breast Cancer: A Single-Arm, Multicenter, Open-Label, Phase II Study.
    Clin Breast Cancer. 2024 Mar 8:S1526-8209(24)00028.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

42. SASADA S, Nagura N, Shimo A, Ogiya A, et al
    Impact of radiation therapy for breast cancer with involved surgical margin after immediate breast reconstruction: A multi-institutional observational study.
    Eur J Surg Oncol. 2024;50:108360.
    PubMed         Abstract available
    
    

    
    Eur Radiol

43. YAN R, Murakami W, Mortazavi S, Yu T, et al
    Quantitative assessment of background parenchymal enhancement is associated with lifetime breast cancer risk in screening MRI.
    Eur Radiol. 2024 Apr 29. doi: 10.1007/s00330-024-10758.
    PubMed         Abstract available
    
    

    
    Int J Cancer

44. BAO Y, Sui X, Wang X, Qu N, et al
    Extrachromosomal circular DNA landscape of breast cancer with lymph node metastasis.
    Int J Cancer. 2024 May 1. doi: 10.1002/ijc.34985.
    PubMed         Abstract available
    
    
45. BRANDT C, Vo JB, Gierach GL, Cheng I, et al
    Second primary cancer risks according to race and ethnicity among U.S. breast cancer survivors.
    Int J Cancer. 2024 Apr 29. doi: 10.1002/ijc.34971.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

46. YONEYAMA M, Zormpas-Petridis K, Robinson R, Sobhani F, et al
    Longitudinal assessment of tumor-infiltrating lymphocytes in primary breast cancer following neoadjuvant radiotherapy.
    Int J Radiat Oncol Biol Phys. 2024 Apr 26:S0360-3016(24)00566.
    PubMed         Abstract available
    
    

    
    J Biol Chem

47. GOEL HL, Karner ER, Kumar A, Mukhopadhyay D, et al
    YAP/TAZ-mediated regulation of laminin 332 is enabled by beta4 integrin repression of ZEB1 to promote ferroptosis resistance.
    J Biol Chem. 2024;300:107202.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

48. 
    Erratum: Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Yea
    J Clin Oncol. 2024 Apr 30:JCO2400711. doi: 10.1200/JCO.24.00711.
    PubMed        
    
    

    
    J Surg Oncol

49. DI PACE B, Padley RH
    Survivorship and breast cancer: Navigating the continuum of care.
    J Surg Oncol. 2024 May 1. doi: 10.1002/jso.27671.
    PubMed        
    
    

    
    JAMA

50. 
    Screening for Breast Cancer.
    JAMA. 2024 Apr 30. doi: 10.1001/jama.2024.5535.
    PubMed        
    
    
51. ELMORE JG, Lee CI
    Toward More Equitable Breast Cancer Outcomes.
    JAMA. 2024 Apr 30. doi: 10.1001/jama.2024.6052.
    PubMed        
    
    
52. CHEN WY, Ballman KV, Partridge AH, Hahn OM, et al
    Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502 Randomized Trial.
    JAMA. 2024 Apr 29:e244840. doi: 10.1001/jama.2024.4840.
    PubMed         Abstract available
    
    
53. HENDERSON JT, Webber EM, Weyrich MS, Miller M, et al
    Screening for Breast Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2024 Apr 30. doi: 10.1001/jama.2023.25844.
    PubMed         Abstract available
    
    
54. NICHOLSON WK, Silverstein M, Wong JB, Barry MJ, et al
    Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2024 Apr 30. doi: 10.1001/jama.2024.5534.
    PubMed         Abstract available
    
    
55. TRENTHAM-DIETZ A, Chapman CH, Jayasekera J, Lowry KP, et al
    Collaborative Modeling to Compare Different Breast Cancer Screening Strategies: A Decision Analysis for the US Preventive Services Task Force.
    JAMA. 2024 Apr 30. doi: 10.1001/jama.2023.24766.
    PubMed         Abstract available
    
    
56. HARRIS E
    Young Patients Without Genetic Risk Have Low Chance of Second Breast Cancer.
    JAMA. 2024 May 3. doi: 10.1001/jama.2024.6734.
    PubMed        
    
    

    
    Lancet

57. DE SOUZA IC, Langer FW
    Post-radiation angiosarcoma of the breast in a patient with a history of invasive ductal carcinoma.
    Lancet. 2024;403:1681-1682.
    PubMed        
    
    

    
    Lancet Oncol

58. FEHM T, Cottone F, Dunton K, Andre F, et al
    Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
    Lancet Oncol. 2024;25:614-625.
    PubMed         Abstract available
    
    

    
    Nat Rev Cancer

59. SHEPARD HM
    Trastuzumab: dreams, desperation and hope.
    Nat Rev Cancer. 2024;24:287-288.
    PubMed        
    
    

    
    NPJ Breast Cancer

60. GOETZ MP, Cicin I, Testa L, Tolaney SM, et al
    Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study.
    NPJ Breast Cancer. 2024;10:34.
    PubMed         Abstract available
    
    

    
    Oncogene

61. LAISNE M, Rodgers B, Benlamara S, Wicinski J, et al
    A novel bioinformatic approach reveals cooperation between Cancer/Testis genes in basal-like breast tumors.
    Oncogene. 2024;43:1369-1385.
    PubMed         Abstract available
    
    
62. DOHENY D, Sirkisoon S, Carpenter RL, Aguayo NR, et al
    Correction: Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis.
    Oncogene. 2024 Apr 27. doi: 10.1038/s41388-024-03046.
    PubMed        
    
    
63. MA J, Chen Y, Li T, Cao Y, et al
    Suppression of lysosome metabolism-meditated GARP/TGF-beta1 complexes specifically depletes regulatory T cells to inhibit breast cancer metastasis.
    Oncogene. 2024 May 2. doi: 10.1038/s41388-024-03043.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

64. BENZEKRY S, Mastri M, Nicolo C, Ebos JML, et al
    Machine-learning and mechanistic modeling of metastatic breast cancer after neoadjuvant treatment.
    PLoS Comput Biol. 2024;20:e1012088.
    PubMed         Abstract available
    
    

    
    PLoS One

65. KIM BK, Kim B, You SH, Jang MS, et al
    Early therapy evaluation of intra-arterial trastuzumab injection in a human breast cancer xenograft model using multiparametric MR imaging.
    PLoS One. 2024;19:e0300171.
    PubMed         Abstract available
    
    
66. LUKASIEWICZ-SMIETANSKA D, Godlewski D, Nowakowska E, Szpak A, et al
    Association of the bitter taste genes TAS2R38 and CA6 and breast cancer risk; a case-control study of Polish women in Poland and Polish immigrants in USA.
    PLoS One. 2024;19:e0300061.
    PubMed         Abstract available
    
    

    
    Radiology

67. COZZI A, Pinker K, Hidber A, Zhang T, et al
    BI-RADS Category Assignments by GPT-3.5, GPT-4, and Google Bard: A Multilanguage Study.
    Radiology. 2024;311:e232133.
    PubMed         Abstract available
    
    
68. BERG WA, Berg JM, Bandos AI, Vargo A, et al
    Addition of Contrast-enhanced Mammography to Tomosynthesis for Breast Cancer Detection in Women with a Personal History of Breast Cancer: Prospective TOCEM Trial Interim Analysis.
    Radiology. 2024;311:e231991.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.